ArticleExploration of targeted anti-tumor therapy2021

The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.

Chiara Tarantelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.